Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2025-11-14)

CHF 15.12+0.53%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

4.50 4 votes No rating yet

NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Financial Performance

For 2024, Newron Pharmaceuticals S.p.A. achieved a net profit of EUR 15.8 million compared to a EUR 16.2 million loss in 2023, with total revenues surging from EUR 9.1 million to EUR 51.4 million. Key financial drivers included EUR 44.5 million in license income and royalty inflows, demonstrating improved operational profitability.

Clinical & Licensing Advances

The evenamide program delivered exceptional data from two pivotal studies, underscoring its efficacy and safety in treatment-resistant and chronic schizophrenia. Additionally, strategic licensing agreements—most notably with EA Pharma/Eisai for the Asian territories and a subsequent deal with Myung In Pharm—provide a prospective earnings stream of up to EUR 117 million and support further clinical development.

Strategic Outlook & Operational Readiness

Looking ahead, Newron is planning a pivotal Phase III randomized, double-blind trial in Q2 2025 and is actively pursuing expansion in other territories. Enhanced by recent board strengthening and capital arrangements, the company’s robust cash resources and licensing proceeds position it well to fund ongoing operations and development initiatives through 2026.

Summarized from source with an LLMView Source

Key figures

98.7%1Y

1,091%3Y

660%5Y

Performance

59.7%1Y

82.6%3Y

73.7%5Y

Volatility